Goldman Sachs Raises Novo Nordisk Price Target
Goldman Sachs has increased its price target for Novo Nordisk shares from 290 to 304 Danish kroner while maintaining a 'Neutral' rating.
Stocks · News reference
Novo Nordisk Announces Share Transactions by Board Members and Executives
Novo Nordisk has published a mandatory disclosure regarding share transactions conducted by its board members, executives, and their associated persons.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Novo Nordisk Appoints New Chief Financial Officer
Novo Nordisk has named Galderma Group CFO Luigi La Corte as its new finance chief.
Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors.
Viking Therapeutics is trading 23% below its recent $35 secondary offering price after raising $575 million for phase 3 development of its weight loss drug VK2735. Despite the post-offering stock decline due to dilution concerns, the article argues this presents a buying opportunity for patient investors, as Viking is advancing dual GLP-1/GIP receptor agonist candidates in injectable and oral formats while the weight loss drug market is projected to reach nearly $100 billion by decade's end.
Novo Nordisk Reports Q3 2026 Results and Raises Full-Year Guidance
Novo Nordisk reported third-quarter 2026 financial results and increased its full-year outlook for sales and adjusted operating profit growth, citing strong momentum in its GLP-1 product portfolio.
Sickle Cell Disease Clinical Trial Pipeline Gains Momentum: 45+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
Over 45 pharmaceutical companies are advancing 50+ pipeline drugs for sickle cell disease treatment. Key developments include Agios Pharmaceuticals' mitapivat receiving FDA Priority Review, Novo Nordisk's etavopivat meeting Phase III endpoints, and CorrectSequence Therapeutics' CS-206 showing sustained vaso-occlusive crisis-free results. The pipeline features diverse mechanisms including PK activators, gene therapies, and fetal hemoglobin stimulants, with approximately 5+ drugs in late-stage development.
Novo Nordisk Provides Update on Share Repurchase Programme
Novo Nordisk reported the latest progress on its ongoing share repurchase program, confirming the number of B shares repurchased as of November 2, 2026.